Recent Updates
Recently added Catalysts
XERS Positive Sentiment

Xeris Announces Details for XP-8121 Program Overview Webinar

Wednesday, August 26, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Xeris Biopharma Holdings, Inc. has announced a webinar to discuss XP-8121, their Phase 3-ready subcutaneous levothyroxine injection for hypothyroidism. The webinar is scheduled for September and aims to provide comprehensive information about the program. This initiative reflects Xeris's commitment to innovative therapies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Xeris is committed to improving patient lives.
  • The XP-8121 program is Phase 3-ready.
  • The webinar aims to provide detailed insights into XP-8121.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+113%
120-day peak, hindsight
Typical move
9.8%
average across 3 past catalysts
Lead asset
Glucagon
Phase 3 · Diabetes Mellitus, Type 1

Full Press Release Details

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced details for a dedicated Program Overview webinar for XP-8121, the Company’s Phase 3-ready, once-weekly subcutaneous levothyroxine injection in development for the treatment of hypothyroidism. The XP-8121 webinar will take place on Wednesday, Septemb

Frequently Asked Questions

What is XP-8121?

XP-8121 is a once-weekly subcutaneous levothyroxine injection for hypothyroidism.

When is the XP-8121 webinar scheduled?

The XP-8121 webinar is scheduled for Wednesday, September.

What is the purpose of the XP-8121 webinar?

The webinar aims to provide a detailed overview of the XP-8121 program.

What phase is XP-8121 currently in?

XP-8121 is Phase 3-ready.

ShareAdd on Google
Tags: XERS Viatris Investor Conferences Healthcare Xeris Biopharma XP-8121 hypothyroidism levothyroxine Phase 3
Last updated: Aug 26, 2026

Biotech snapshot

Cash runway
$122M liquidity · $0M/mo burn
Low dilution risk
Lead asset
GlucagonPhase 3
Diabetes Mellitus, Type 1 →

Catalyst track record

+113%
best trade around XERS's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for XERS.

See every catalyst's timing & PoA →